<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TIGECYCLINE</span><br/>(ti-ge-cy'cline)<br/><span class="topboxtradename">Tygacil<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">tetracycline</span>; <span class="classification">glycylcycline </span><br/><b>Prototype: </b>Tetracycline<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg lyophilized powder </p>
<h1><a name="action">Actions</a></h1>
<p>Tigecycline inhibits protein production in bacteria by binding to the 30S ribosomal subunit and blocking entry of transfer
         RNA molecules into the ribosome of the bacteria. This prevents formation of peptide chains in bacteria, thus interfering with
         their growth.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Tigecycline is active against a broad spectrum of bacterial pathogens and is bacteriostatic. </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of complicated skin and skin structure infections and complicated intraabdominal infections. Organisms susceptible
         to tigecycline include <i>Escherichia coli</i>, <i>Enterococcus faecalis</i> (vancomycin-susceptible isolates only), <i>Staphylococcus</i> [<i>S. aureus</i> (methicillin-susceptible and methicillin-resistant isolates)], <i>Streptococcus [S. agalactiae</i>, <i>S. anginosus</i> group (includes <i>S. anginosus</i>, <i>S. intermedius</i>, and <i>S. constellatus), S. pyogenes], Citrobacter freundii, Enterobacter cloaca, Klebsiella (K. oxytoca, K. pneumoniae), Bacteroides
            (B. fragilis, B. thetaiotaomicron, B. uniformis, B. vulgatus), Clostridium perfringens</i>, and <i>Peptostreptococcus micros.</i>
</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment of <i>Acinetobacter baumannii, Aeromonas hydrophila, Bacteroides (B. distasonis</i> and <i>B. ovatus), Citrobacter koseri, Enterobacter aerogenes, Entercoccus [E. casseliflavus, E. faecalis</i> (vancomycin-resistant isolates), <i>E. faecium</i> (vancomycin-susceptible and -resistant isolates), <i>E. gallinarum], Listeria monocytogenes, Mycobacterium (M. abscessus, M. chelonae, M. fortuitum), Pasteurella multocida, Peptostreptococcus</i> sp., <i>Porphyromonas</i> sp., <i>Prevotella</i> sp., <i>Serratia marcescens, Staphylococci (S. epidermidis, S. haemolyticus),</i> and <i>Stenotrophomonas maltophilia.</i>
</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to tigecycline; pregnancy (category D) and during tooth development of the fetus; viral infections.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Severe hepatic impairment (Child-Pugh class C); hypersensitivity to tetracycline, intestinal perforations, intraabdominal
         infections; children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Complicated Skin and Intraabdominal Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 100 mg initially, followed by 50 mg q12h over 3060 min<br/><br/><span class="impairmenttitle">Hepatic Impairment</span><br/><span class="rdage">Child-Pugh class C:</span> <span class="rdroute"></span> Initial dose 100 mg, followed by 25 mg q12h<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>Note that dosage adjustment is required with severe hepatic impairment.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent:</span> Reconstitute each vial (50 mg) with 5.3 mL of NS or D5W to yield 10 mg/mL. Swirl gently to dissolve; reconstituted solution
                  should be yellow to orange in color. After reconstitution, immediately withdraw the solution and add to 100 mL IV bag of NS
                  or D5W for infusion. The maximum concentration in the IV bag should be 1 mg/mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Intermittent:</span> Give over 3060 min; when using Y-site, flush IV line with NS or D5W before/after infusion.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Y-site:</span>
<b>Amphotericin,</b>
<b>chlorpromazine,</b>
<b>methylprednisolone sodium succinate,</b>
<b>voriconazole.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store in the IV bag at room temperature for up to 6 h, or refrigerated at 2°8° C (36°46° F)
            for up to 24 h.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Asthenia, dizziness, headache, insomnia. <span class="typehead">CV:</span> Hypertension, hypotension, peripheral edema, phlebitis. <span class="typehead">GI:</span> Abdominal pain, constipation, diarrhea, dyspepsia, <span class="speceff-common">nausea, vomiting</span>. <span class="typehead">Hepatologic/Lymphatic:</span> Abnormal healing, anemia, infection, leukocytosis, thrombocythemia. <span class="typehead">Metabolic/Nutritional:</span> Alkaline phosphatase increased, ALT increased, amylase increased, AST increased, bilirubinemia, BUN increased, hyperglycemia,
      hypokalemia, hypoproteinemia, lactic dehydrogenase increased. <span class="typehead">Musculoskeletal:</span> Back pain.  <span class="typehead">Respiratory:</span> Dyspnea, increased cough, pulmonary physical findings. <span class="typehead">Skin:</span> Pruritus, rash, sweating. <span class="typehead">Body as a Whole:</span> Abscess, fever, local reaction to injection, pain. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Increased concentrations of <b>warfarin</b> required close monitoring of INR. Efficacy of <span class="classification">oral contraceptives</span> may be decreased when used in combination with tigecycline. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> 7189% protein bound. <span class="typehead">Metabolism:</span> Negligible. <span class="typehead">Elimination:</span> Fecal (major) and renal. <span class="typehead">Half-Life:</span> 27 h (single dose) and 42 h (multiple doses). 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for hypersensitivity reaction in those with reported tetracycline allergy.</li>
<li>Monitor for and report S&amp;S of superinfection (see Appendix F) or pseudomembranous enterocolitis (see Appendix F).</li>
<li>Lab tests: C&amp;S prior to initiation of therapy; periodic serum electrolytes, LFTs and kidney function tests; PT and INT with
            concurrent anticoagulant therapy.
         </li>
<li>Monitor diabetics for loss of glycemic control.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Avoid direct exposure to sunlight during and for several days after therapy is terminated to reduce risk of photosensitivity
            reaction.
         </li>
<li>Report to physician loose stools or diarrhea either during or shortly after termination of therapy.</li>
<li>Use a barrier contraceptive in addition to oral contraceptives if trying to avoid pregnancy. </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>